CT-101a

N/A

Report date: 2023/05/17 20:00:39

Base Information

Drug NameCT-101a
Drug Alias NameCT-101a
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesZhejiang UniversitySuzhou Zeke Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZhejiang University
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A